Analysts Anticipate Cytori Therapeutics Inc (CYTX) to Announce ($0.05) EPS

Shares of Cytori Therapeutics Inc (NASDAQ:CYTX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating. Cytori Therapeutics’ rating score has improved by 50% from three months ago as a result of various analysts’ ratings changes.

Brokers have set a 12-month consensus price target of $1.45 for the company and are expecting that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also assigned Cytori Therapeutics an industry rank of 167 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

A number of equities analysts have recently issued reports on the company. Maxim Group set a $2.00 price target on Cytori Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 28th. ValuEngine downgraded Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Zacks Investment Research downgraded Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 8th. B. Riley raised Cytori Therapeutics from a “neutral” rating to a “buy” rating in a research report on Friday, March 9th. Finally, Laidlaw reissued a “buy” rating and set a $1.65 price target on shares of Cytori Therapeutics in a research report on Thursday, February 22nd.

In other Cytori Therapeutics news, major shareholder Ag Postfinance sold 286,982 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $0.31, for a total value of $88,964.42. Following the completion of the sale, the insider now directly owns 5,118,627 shares in the company, valued at $1,586,774.37. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.80% of the company’s stock.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. raised its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 612,304 shares of the biotechnology company’s stock after buying an additional 275,653 shares during the quarter. Vanguard Group Inc. owned about 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent reporting period. 6.03% of the stock is owned by hedge funds and other institutional investors.

CYTX opened at $0.28 on Friday. Cytori Therapeutics has a 12-month low of $0.22 and a 12-month high of $1.21. The firm has a market cap of $17.38, a PE ratio of -0.43 and a beta of 3.13.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Cytori Therapeutics had a negative return on equity of 210.47% and a negative net margin of 418.36%. The firm had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.00 million. research analysts forecast that Cytori Therapeutics will post -0.18 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate Cytori Therapeutics Inc (CYTX) to Announce ($0.05) EPS” was reported by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Get a free copy of the Zacks research report on Cytori Therapeutics (CYTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply